Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants.

J Korean Med Sci · 2019 · PMC6374546 · PMID 30787683

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)

13 In the Comparison of Acute Treatments in Cancer Haemostasis (CATCH) trial, the largest phase III randomized trial comparing LMWH to WFR, patients treated with the tinzaparin showed a trend toward reduction in VTE recurrence (7.2% for tinzaparin vs. 10.5% for WFR; HR, 0.65; 95% CI, 0.41–1.03; P = 0.07), but the difference was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.